Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG

Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease

Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04389.2000 · Cited by 522

Increased oxidative damage to DNA in ALS patients

Bogdanov, M. B., Brown, R. H., Matson, W. R., Smart, R. J., Hayden, D. L., O’Donnell, H. C., Beal, M. F., & Cudkowicz, M. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00349-x · Cited by 334

Oxidative stress in patients with Friedreich ataxia

Schulz, J. B., Dehmer, T., Schöls, L. J., Mende, H. E., Hardt, C., Vorgerd, M., Bürk, K., Matson, W. R., DICHGANS, J., Beal, M. F., et al. (2000) · Neurology · doi:10.1212/wnl.55.11.1719 · Cited by 305

Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease

Andreassen, O. A., Dedeoglu, A., Ferrante, R. J., Jenkins, B. G., Ferrante, K. L., Thomas, M., Friedlich, A., Browne, S. E., Schilling, G., Borchelt, D. R., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0406 · Cited by 293

Increase of total creatine in human brain after oral supplementation of creatine-monohydrate

Dechent, P., Pouwels, P. J. W., Wilken, B., Hanefeld, F., & Frahm, J. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.277.3.r698 · Cited by 221

A carbon column-based liquid chromatography electrochemical approach to routine 8-hydroxy-2′-deoxyguanosine measurements in urine and other biologic matrices: a one-year evaluation of methods

Bogdanov, M. B., Beal, M. F., McCabe, D. R., Griffin, R. M., & Matson, W. R. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00113-6 · Cited by 179

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

Dedeoglu, A., Kubilus, J. K., Yang, L., Ferrante, K. L., Hersch, S. M., Beal, M. F., & Ferrante, A. R. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01706.x · Cited by 169

Creatine supplementation in Huntington’s disease

Verbessem, P., Lemiere, J., Eijnde, B. O., Swinnen, S. P., Vanhees, L., Leemputte, M. V., Hespel, P., & Dom, R. (2003) · Neurology · doi:10.1212/01.wnl.0000090629.40891.4b · Cited by 163

Creatine therapy for Huntington’s disease: Clinical and MRS findings in a 1-year pilot study

Tabrizi, S. J., Blamire, A. M., Manners, D. N., Rajagopalan, B., Styles, P., Schapira, A. H. V., & Warner, T. T. (2003) · Neurology · doi:10.1212/01.wnl.0000070186.97463.a7 · Cited by 87

Non-Invasive Neurochemical Analysis of Focal Excitotoxic Lesions in Models of Neurodegenerative Illness Using Spectroscopic Imaging

Jenkins, B. G., Brouillet, E., Chen, Y. I., Storey, E., Schulz, J. B., Kirschner, P. B., Beal, M. F., & Rosen, B. R. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199605000-00011 · Cited by 84

A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS

Gordon, P. H., Cheung, Y. K., Levin, B. L., Andrews, H., Doorish, C., MacArthur, R. B., Montes, J., Bednarz, K., Florence, J. M., Rowin, J., et al. (2008) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960802195632 · Cited by 70

Advances in the Pharmacological Management of Huntingtonʼs Disease

Frank, S., & Jankovic, J. J. (2010) · Drugs · doi:10.2165/11534430-000000000-00000 · Cited by 71

Protective Effects of Antioxidants in Huntington’s Disease: an Extensive Review

Essa, M. M., Moghadas, M., Ba-Omar, T., Qoronfleh, M. W., Guillemin, G. J., Manivasagam, T., Justin‐Thenmozhi, A., Ray, B., Bhat, A., Chidambaram, S. B., et al. (2019) · Neurotoxicity Research · doi:10.1007/s12640-018-9989-9 · Cited by 68

Ammonia toxicity to the brain: Effects on creatine metabolism and transport and protective roles of creatine

Braissant, O. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.02.011 · Cited by 67

Glutathione redox cycle dysregulation in Huntington’s disease knock-in striatal cells

Ribeiro, M., Rosenstock, T. R., Cunha‐Oliveira, T., Ferreira, I. L., Oliveira, C. R., & Rego, A. C. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.09.004 · Cited by 67

Guanidinoacetate Is More Effective than Creatine at Enhancing Tissue Creatine Stores while Consequently Limiting Methionine Availability in Yucatan Miniature Pigs

McBreairty, L. E., Robinson, J. L., Furlong, K., Brunton, J. A., & Bertolo, R. F. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131563 · Cited by 63

Targeting mitochondrial dysfunction in neurodegenerative disease: Part I

Burchell, V., Gandhi, S., Deas, E., Wood, N. W., Abramov, A. Y., & Plun‐Favreau, H. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003652489 · Cited by 64

Creatine as a Neuroprotector: an Actor that Can Play Many Parts

Marques, E. P., & Wyse, Â. T. D. S. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00053-7 · Cited by 62

Parkinsonism and Related Disorders

Slow, E., & Lang, A. E. (2019) · DeckerMed Transitional Year Weekly Curriculum™ · doi:10.2310/tywc.1178 · Cited by 62

Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects

Szalárdy, L., Klivènyi, P., Zádori, D., Fülöp, F., Toldi, J., & Vécsei, L. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800167365 · Cited by 60

Huntington's disease: An update of therapeutic strategies

Kumar, A., Singh, S. K., Kumar, V., Kumar, D., Agarwal, S., & Rana, M. K. (2014) · Gene · doi:10.1016/j.gene.2014.11.022 · Cited by 62

Huntington's Disease: Pathological Mechanisms and Therapeutic Strategies

Ramaswamy, S., Shannon, K. M., & Kordower, J. H. (2007) · Cell Transplantation · doi:10.3727/000000007783464687 · Cited by 59

Potential biomarkers to follow the progression and treatment response of Huntington’s disease

Disatnik, M.-H., Joshi, A. U., Saw, N. L., Shamloo, M., Leavitt, B. R., Qi, X., & Mochly-Rosen, D. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160776 · Cited by 58

An evidence-based approach in the treatment of Huntington’s disease

Mestre, T., & Ferreira, J. J. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.10.021 · Cited by 57

Natalizumab and progressive multifocal leucoencephalopathy

Berger, J. R. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.058404 · Cited by 57

The Neuroprotective Role of Creatine

Klein, A., & Ferrante, R. J. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6486-9_11 · Cited by 56

Fluid and imaging biomarkers for Huntington's disease

Zeun, P., Scahill, R. I., Tabrizi, S. J., & Wild, E. J. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.02.004 · Cited by 58

The Evolving Applications of Creatine Supplementation: Could Creatine Improve Vascular Health?

Clarke, H. E., Kim, D., Meza, C., Ormsbee, M. J., & Hickner, R. C. (2020) · Nutrients · doi:10.3390/nu12092834 · Cited by 58

The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia

Escribano, B. M., Colín-González, A. L., Santamarı́a, A., & Túnez, I. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140806160400 · Cited by 53

A Critical Evaluation of Wet Biomarkers for Huntington’s Disease: Current Status and Ways Forward

Silajdžić, E., & Björkqvist, M. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-170273 · Cited by 56

Mitochondrial Enhancement for Neurodegenerative Movement Disorders: A Systematic Review of Trials Involving Creatine, Coenzyme Q10, Idebenone and Mitoquinone

Liu, J., & Wang, L. (2013) · CNS Drugs · doi:10.1007/s40263-013-0124-4 · Cited by 53

Free radical biology in neurological manifestations: mechanisms to therapeutics interventions

Tripathi, R. S., Gupta, R. V., Sahu, M., Srivastava, D., Das, A., Ambasta, R. K., & Kumar, P. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16693-2 · Cited by 54

Creatine Supplementation Beyond Athletics: Benefits of Different Types of Creatine for Women, Vegans, and Clinical Populations—A Narrative Review

Gutiérrez‐Hellín, J., Coso, J. D., Franco-Andrés, A., Gamonales, J. M., Espada, M. C., González‐García, J., López‐Moreno, M., & Varillas‐Delgado, D. (2024) · Nutrients · doi:10.3390/nu17010095 · Cited by 56

Analyzing the Functional Properties of the Creatine Kinase System with Multiscale ‘Sloppy’ Modeling

Hettling, H., & van Beek, H. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002130 · Cited by 55

Oxidative stress is increased in C. elegans models of Huntington’s disease but does not contribute to polyglutamine toxicity phenotypes

Machiela, E., Dues, D. J., Senchuk, M. M., & Raamsdonk, J. M. V. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.08.008 · Cited by 53

Complexity and Heterogeneity: What Drives the Ever‐changing Brain in Huntington's Disease?

Rosas, H. D., Salat, D. H., Lee, S. Y., Zaleta, A. K., Hevelone, N. D., & Hersch, S. M. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.034 · Cited by 51

Advances in mass spectrometry-based multi-scale metabolomic methodologies and their applications in biological and clinical investigations

Wang, Z., Zhu, H., & Xiong, W. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.08.047 · Cited by 55

Reactive Species in Huntington Disease: Are They Really the Radicals You Want to Catch?

Bono-Yagüe, J., Gómez-Escribano, A. P., Millán, J. M., & Vázquez‐Manrique, R. P. (2020) · Antioxidants · doi:10.3390/antiox9070577 · Cited by 52

Creatine in mouse models of neurodegeneration and aging

Klopstock, T., Elstner, M., & Bender, A. (2011) · Amino Acids · doi:10.1007/s00726-011-0850-1 · Cited by 49

Mechanisms of Mitochondrial Malfunction in Alzheimer’s Disease: New Therapeutic Hope

Nabi, S. U., Khan, A., Siddiqui, E. M., Rehman, M. U., Alshahrani, S., Arafah, A. M., Mehan, S., Alsaffar, R. M., Alexiou, A. T., & Shen, B. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/4759963 · Cited by 51

Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration

Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00184 · Cited by 53

An MDS Evidence‐Based Review on Treatments for Huntington's Disease

Ferreira, J. J., Rodrigues, F. B., Duarte, G. S., Mestre, T., Bachoud‐Lévi, A., Bentivoglio, A. R., Burgunder, J., Cardoso, F., Claassen, D. O., Landwehrmeyer, G. B., et al. (2021) · Movement Disorders · doi:10.1002/mds.28855 · Cited by 47

Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics

Ross, C. A., & Shoulson, I. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70800-4 · Cited by 47

Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease

Kim, J., Amante, D. J., Moody, J. P., Edgerly, C. K., Bordiuk, O. L., Smith, K., Matson, S. A., Matson, W. R., Scherzer, C. R., Rosas, H. D., et al. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.05.001 · Cited by 47

Brain levels of high-energy phosphate metabolites and executive function in geriatric depression

Harper, D. G., Joe, E., Jensen, J. E., Ravichandran, C. T., & Forester, B. P. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4439 · Cited by 48

2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease

Wu, B., Jiang, M., Peng, Q., Li, G., Hou, Z., Milne, G. L., Mori, S., Alonso, R. J., Geisler, J. G., & Duan, W. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.03.020 · Cited by 46

Creatine for treating muscle disorders

Kley, R. A., Vorgerd, M., & Tarnopolsky, M. A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub2 · Cited by 45

Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation

Choi, J., Küstermann, E., Dedeoglu, A., & Jenkins, B. G. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.07015.x · Cited by 46

Protective effects of 3-alkyl luteolin derivatives are mediated by Nrf2 transcriptional activity and decreased oxidative stress in Huntington's disease mouse striatal cells

Oliveira, A. M., Cardoso, S. M., Ribeiro, M., Seixas, R. S. G. R., Silva, A. M. S., & Rego, A. C. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.10.004 · Cited by 44

Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes

Moreira, P. I., Cardoso, S. M., Pereira, C., Santos, M. S., & Oliveira, C. R. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824651 · Cited by 44

Mitochondrial Energy Depletion in Depression with Somatization

Gardner, A., & Boles, R. G. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112891 · Cited by 44

Neuroprotection for Huntington’s Disease: Ready, Set, Slow

Hersch, S. M., & Rosas, H. D. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.01.003 · Cited by 44

Therapeutic use of creatine in brain or heart ischemia: Available data and future perspectives

Perasso, L., Spallarossa, P., Gandolfo, C., Ruggeri, P., & Balestrino, M. (2013) · Medicinal Research Reviews · doi:10.1002/med.20255 · Cited by 43

Metabolism in HD: Still a relevant mechanism?

Duan, W., Jiang, M., & Jin, J. (2014) · Movement Disorders · doi:10.1002/mds.25992 · Cited by 41

Cell Rearrangement and Oxidant/Antioxidant Imbalance in Huntington’s Disease

D’Egidio, F., Castelli, V., Cimini, A., & d’Angelo, M. (2023) · Antioxidants · doi:10.3390/antiox12030571 · Cited by 42

Huntington's Disease: Advocacy Driving Science

Wexler, N. S. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-050710-134457 · Cited by 40

Metabolomics in degenerative brain diseases

Escobar, M. Q., Pontes, J. G. D. M., & Tasić, L. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147704 · Cited by 41

Bioenergetic‐based neuroprotection and glaucoma

Schober, M. S., Chidlow, G., Wood, J. P. M., & Casson, R. J. (2008) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2008.01740.x · Cited by 40

Huntington's disease: progress and potential in the field

Stack, E. C., & Ferrante, R. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.12.1933 · Cited by 39

Creatine for treating muscle disorders

Kley, R. A., Tarnopolsky, M. A., & Vorgerd, M. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub3 · Cited by 38

Accumulation of oxidative stress around the stroke-like lesions of MELAS patients

Katayama, Y., Maeda, K., Iizuka, T., Hayashi, M., Hashizume, Y., Sanada, M., Kawai, H., & Kashiwagi, A. (2009) · Mitochondrion · doi:10.1016/j.mito.2009.04.002 · Cited by 37

Oxidizing Effects of Exogenous Stressors in Huntington’s Disease Knock-in Striatal Cells—Protective Effect of Cystamine and Creatine

Ribeiro, M., da Silva, A. B. G., Rodrigues, J., Naia, L., & Rego, A. C. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft199 · Cited by 37

Therapeutic Strategies in Huntington’s Disease: From Genetic Defect to Gene Therapy

Jurcău, A., & Jurcău, M. C. (2022) · Biomedicines · doi:10.3390/biomedicines10081895 · Cited by 37

New Directions in Therapeutics for Huntington Disease

Potkin, K. T., & Potkin, S. G. (2018) · Future Neurology · doi:10.2217/fnl-2017-0035 · Cited by 36

Huntington’s Disease Clinical Trials Corner: June 2019

Rodrigues, F. B., Ferreira, J. J., & Wild, E. J. (2019) · Journal of Huntington s Disease · doi:10.3233/jhd-199003 · Cited by 36

Increased mitochondrial DNA oxidative damage after transient middle cerebral artery occlusion in mice

Ohtaki, H., Takeda, T., Dohi, K., Yofu, S., Nakamachi, T., Satoh, K., Hiraizumi, Y., Miyaoka, H., Matsunaga, M., & Shioda, S. (2007) · Neuroscience Research · doi:10.1016/j.neures.2007.04.005 · Cited by 35

Neuroprotective Effects of Creatine in the CMVMJD135 Mouse Model of Spinocerebellar Ataxia Type 3

Duarte‐Silva, S., Neves‐Carvalho, A., Soares‐Cunha, C., Silva, J. M., Teixeira‐Castro, A., Vieira, R., Silva‐Fernandes, A., & Maciel, P. (2018) · Movement Disorders · doi:10.1002/mds.27292 · Cited by 34

Creatine increases hippocampal Na+,K+-ATPase activity via NMDA–calcineurin pathway

Rambo, L. M., Ribeiro, L. R., Schramm, V., Bersch, A. M., Stamm, D. N., Della-Pace, I. D., Silva, L. F. A., Furian, A. F., Oliveira, M. S., Fighera, M. R., et al. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.06.007 · Cited by 34

What, When and How to Measure—Peripheral Biomarkers in Therapy of Huntington’s Disease

Przybył, Ł., Woźna, M., Kozłowska, E., & Fiszer, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041561 · Cited by 33

Metabolism in Huntington’s disease: a major contributor to pathology

Singh, A., & Agrawal, N. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00844-y · Cited by 34

Nrf2 Pathway in Huntington’s Disease (HD): What Is Its Role?

Tucci, P., Lattanzi, R., Severini, C., & Saso, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315272 · Cited by 33

Comparison of vertical and horizontal saccade measures and their relation to gray matter changes in premanifest and manifest Huntington disease

Rupp, J., Džemidžić, M., Blekher, T., West, J. D., Hui, S. L., Wojcieszek, J., Saykin, A. J., Kareken, D. A., & Foroud, T. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6172-0 · Cited by 35

Stuck at the bench: Potential natural neuroprotective compounds for concussion

Petraglia, A. L., Bailes, J., & Winkler, E. (2011) · Surgical Neurology International · doi:10.4103/2152-7806.85987 · Cited by 36

Huntington’s Disease Clinical Trials Corner: August 2018

Rodrigues, F. B., & Wild, E. J. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-189003 · Cited by 33

Therapeutic approaches to preventing cell death in Huntington disease

Kaplan, A. R., & Stockwell, B. R. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.08.004 · Cited by 32

Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/electrochemical array/mass spectrometry and off-line tandem mass spectrometry

Ebbel, E. N., Leymarie, N., Schiavo, S., Sharma, S., Gevorkian, S., Hersch, S. M., Matson, W. R., & Costello, C. E. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.01.010 · Cited by 32

Mitochondria and neurodegenerative diseases: the promising role of nanotechnology in targeted drug delivery

Pezzini, I., Mattoli, V., & Ciofani, G. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1218461 · Cited by 32

Urinary 8‐OHdG elevations in a partial lesion rat model of parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion

Kikuchi, Y., Yasuhara, T., Agari, T., Kondo, A., Kuramoto, S., Kameda, M., Kadota, T., Baba, T., Tajiri, N., Wang, F., et al. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22467 · Cited by 31

Biomechanistic insights into the roles of oxidative stress in generating complex neurological disorders

Yusuf, M., Khan, M., Robaian, M. A., & Khan, R. A. (2017) · Biological Chemistry · doi:10.1515/hsz-2017-0250 · Cited by 32

Mitochondrial functional alterations in relation to pathophysiology of Huntington’s disease

Pandey, M., Mohanakumar, K. P., & Rajamma, U. (2010) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-010-9288-5 · Cited by 30

Neurodegenerative Diseases: New Hopes and Perspectives

Bhat, M. A., & Dhaneshwar, S. S. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230907093451 · Cited by 29

Influence of intensive multifunctional neuro - rehabilitation on neuronal oxidative damage in patients with Huntington?s disease

Ciancarelli, I. (2015) · Functional Neurology · doi:10.11138/fneur/2015.30.1.047 · Cited by 28

Biofluid Biomarkers in Huntington’s Disease

Rodrigues, F. B., Byrne, L. M., & Wild, E. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7825-0_17 · Cited by 30

The updated development of blood-based biomarkers for Huntington’s disease

Zhang, S., Cheng, Y., & Shang, H. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11572-x · Cited by 28

8OHdG is not a biomarker for Huntington disease state or progression

Borowsky, B., Warner, J., Leavitt, B. R., Tabrizi, S. J., Roos, R. A. C., Dürr, A., Becker, C., Sampaio, C., Tobin, A. J., & Schulman, H. (2013) · Neurology · doi:10.1212/wnl.0b013e318293e1a1 · Cited by 26

Blood Oxidative Stress Marker Aberrations in Patients with Huntington’s Disease: A Meta-Analysis Study

Tang, Q., Liu, H., Shi, X., & Cheng, Y. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9187195 · Cited by 25

Mouse Models for Validating Preclinical Candidates for Huntington's Disease

Yang, X. W., & Gray, M. (2010) · Frontiers in neuroscience · doi:10.1201/ebk0849390005-c7 · Cited by 27

Therapeutics in Huntington’s Disease

Killoran, A., & Biglan, K. (2012) · Current Treatment Options in Neurology · doi:10.1007/s11940-012-0165-x · Cited by 23

Biomarker development for Huntington's disease

André, R., Scahill, R. I., Salman, H., & Tabrizi, S. J. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.002 · Cited by 23

Peripheral biomarkers of oxidative stress and their limited potential in evaluation of clinical features of Huntington's patients

Ciancarelli, I., Amicis, D. D., Massimo, C. D., Scanno, C. D., Pistarini, C., D’Orazio, N., & Ciancarelli, M. G. T. (2014) · Biomarkers · doi:10.3109/1354750x.2014.935955 · Cited by 23

New opportunities for antioxidants in amelioration of neurodegenerative diseases

Bhandari, U. R., Danish, S. M., Ahmad, S., Ikram, M., Nadaf, A., Hasan, N., Kesharwani, P., & Ahmad, F. J. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.111961 · Cited by 24

An Update of Kaempferol Protection against Brain Damage Induced by Ischemia-Reperfusion and by 3-Nitropropionic Acid

López‐Sánchez, C., Lagoa, R., Poejo, J., García‐López, V., García‐Martínez, V., & Gutiérrez‐Merino, C. (2024) · Molecules · doi:10.3390/molecules29040776 · Cited by 21

Biomarkers for Huntington's disease: A brief overview

Killoran, A. (2016) · Journal of Rare Diseases Research & Treatment · doi:10.29245/2572-9411/2016/2.1029 · Cited by 21

Molecular biology of Huntington's disease

McFarland, K. N., & Cha, J.-H. J. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52014-2.00003-3 · Cited by 21

Creatine prevents the inhibition of energy metabolism and lipid peroxidation in rats subjected to GAA administration

Kolling, J., & Wyse, Â. T. D. S. (2010) · Metabolic Brain Disease · doi:10.1007/s11011-010-9215-9 · Cited by 21

A mitochondrial basis for Huntington’s disease: therapeutic prospects

Chakraborty, J., Rajamma, U., & Mohanakumar, K. P. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1951-9 · Cited by 21

Long term creatine monohydrate supplementation, following neonatal hypoxic ischemic insult, improves neuromuscular coordination and spatial learning in male albino mouse

Iqbal, S., Ali, M. A., & Iqbal, F. (2014) · Brain Research · doi:10.1016/j.brainres.2014.10.006 · Cited by 20

Altered Aconitase 2 Activity in Huntington’s Disease Peripheral Blood Cells and Mouse Model Striatum

Chen, C., Wu, Y., & Chang, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112480 · Cited by 20

Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts

Esteves, S., Duarte‐Silva, S., & Maciel, P. (2016) · Medicinal Research Reviews · doi:10.1002/med.21425 · Cited by 22

Non-invasive assessment of disease progression and neuroprotective effects of dietary coconut oil supplementation in the ALS SOD1G93A mouse model: A 1H-magnetic resonance spectroscopic study

Weerasekera, A., Sima, D. M., Dresselaers, T., Huffel, S. V., Damme, P. V., & Himmelreich, U. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.09.011 · Cited by 20

28 days of creatine nitrate supplementation is apparently safe in healthy individuals

Joy, J. M., Lowery, R. P., Falcone, P. H., Mosman, M. M., Vogel, R. M., Carson, L. R., Tai, C.-Y., Choate, D., Kimber, D., Ormes, J. A., et al. (2014) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-014-0060-9 · Cited by 19

HSF1 and Its Role in Huntington’s Disease Pathology

Kim, H., & Gómez‐Pastor, R. (2022) · Advances in experimental medicine and biology · doi:10.1007/5584_2022_742 · Cited by 21

Experimental Models of HD and Reflection on Therapeutic Strategies

Kim, J., Bordiuk, O. L., & Ferrante, R. J. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-381328-2.00016-x · Cited by 20

Mitochondrial and metabolic-based protective strategies in Huntington’s disease: the case of creatine and coenzyme Q

Naia, L., Ribeiro, M. J., & Rego, A. C. (2011) · Reviews in the Neurosciences · doi:10.1515/rns.2011.060 · Cited by 19

Huntington’s Disease: Clinical Features and Routes to Therapy

Paulson, H. L., & Albin, R. L. (2011) · Europe PMC (PubMed Central) · Cited by 19

In Vivo Nanodiamond Quantum Sensing of Free Radicals in Caenorhabditis elegans Models

Fan, S., Zhang, Y., Ainslie, A. P., Seinstra, R. I., Zhang, T., Nollen, E. A. A., & Schirhagl, R. (2025) · Advanced Science · doi:10.1002/advs.202412300 · Cited by 18

Lack of Efficacy of 5 Grams Daily of Creatine in Schizophrenia

Kaptsan, A., Odessky, A., Osher, Y., & Levine, J. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0609 · Cited by 18

Network mirroring for drug repositioning

Park, S., Lee, D. A., & Shin, H. (2017) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-017-0449-x · Cited by 18

Low Tissue Creatine: A Therapeutic Target in Clinical Nutrition

Ostojić, S. M. (2022) · Nutrients · doi:10.3390/nu14061230 · Cited by 17

Uridine ameliorates the pathological phenotype in transgenic G93A-ALS mice

Amante, D. J., Kim, J.-H., Carreiro, S. T., Cooper, A. C., Jones, S. W., Li, T., Moody, J. P., Edgerly, C. K., Bordiuk, O. L., Cormier, K., et al. (2010) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482968.2010.491867 · Cited by 18

Creatine may reduce oxidative injury in Huntington's disease

&NA; (2006) · Inpharma Weekly · doi:10.2165/00128413-200615290-00038

Creatine supplementation lowers brain glutamate levels in Huntington?s disease

Bender, A., Auer, D. P., Merl, T., Reilmann, R., Saemann, P., Yassouridis, A., Bender, J., Weindl, A., Dose, M., Gasser, T., et al. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0595-4 · Cited by 129

Creatine supplementation in Huntington’s disease

Verbessem, P., Lemiere, J., Eijnde, B. O., Swinnen, S. P., Vanhees, L., Leemputte, M. V., Hespel, P., & Dom, R. (2003) · Neurology · doi:10.1212/01.wnl.0000090629.40891.4b · Cited by 163

PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease

Rosas, H. D., Doros, G. D., Gevorkian, S., Malarick, K., Reuter, M., Coutu, J., Triggs, T. D., Wilkens, P. J., Matson, W. R., Salat, D. H., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000187 · Cited by 98

Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease

Andreassen, O. A., Dedeoglu, A., Ferrante, R. J., Jenkins, B. G., Ferrante, K. L., Thomas, M., Friedlich, A., Browne, S. E., Schilling, G., Borchelt, D. R., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0406 · Cited by 293